Form 4: CareDx Director Fred Cohen Reports Acquisition of Restricted Stock Units

CareDx, Inc. Director Fred E. Cohen reported the acquisition of 12,103 restricted stock units, a non-cash transaction, effective June 13, 2025, increasing his direct beneficial ownership to 155,265 shares.

Summary

• Fred E. Cohen, a Director of CareDx, Inc. (CDNA), reported the acquisition of 12,103 shares of common stock.
• The transaction occurred on June 13, 2025.
• The shares were acquired at a price of $0, indicating they are restricted stock units (RSUs).
• Following this transaction, Mr. Cohen's direct beneficial ownership in CareDx, Inc. increased to 155,265 shares.
• The RSUs are scheduled to vest in one installment on the earlier of June 13, 2026, or the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is generally a neutral to slightly positive event, as it aligns the director's financial interests with the long-term performance of the company's stock, signaling commitment and confidence.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• An increase in beneficial ownership by a director can signal confidence in the company's future prospects.

Risks

• The value of the restricted stock units is subject to the future performance of CareDx, Inc.'s common stock.
• The vesting of the RSUs is contingent upon continued service as a director until the vesting date.

Future Outlook

The 12,103 restricted stock units granted to Director Fred E. Cohen are scheduled to vest in a single installment on the earlier of June 13, 2026, or the day immediately preceding the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025.

Industry Context

This Form 4 filing reflects a standard practice of compensating directors with equity, aligning their interests with long-term shareholder value. Such grants are common across the biotechnology and healthcare diagnostics industries, where CareDx operates.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to directors is a common compensation practice in publicly traded companies, particularly in the technology and healthcare sectors, aligning director incentives with shareholder returns.
• The specific number of units granted (12,103) and the total beneficial ownership (155,265 shares) would typically be evaluated against peer companies' director compensation packages and ownership levels, though specific comparable companies or projects are not detailed in this filing.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially fostering decisions that enhance long-term stock value.

Next Steps

• The vesting of the 12,103 restricted stock units on the earlier of June 13, 2026, or the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025.

Key Dates

Keywords

CareDx, CDNA, Fred E. Cohen, Form 4, SEC filing, insider transaction, restricted stock units, RSU grant, director compensation, beneficial ownership